Your browser doesn't support javascript.
loading
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
Subiela, José Daniel; Krajewski, Wojciech; González-Padilla, Daniel A; Laszkiewicz, Jan; Taborda, Javier; Aumatell, Júlia; Sanchez Encinas, Miguel; Basile, Giuseppe; Moschini, Marco; Caño-Velasco, Jorge; Lopez Perez, Enrique; Del Olmo Durán, Pedro; Gallioli, Andrea; Tukiendorf, Andrzej; D'Andrea, David; Yuen-Chun Teoh, Jeremy; Serna Céspedes, Alejandra; Pichler, Renate; Afferi, Luca; Del Giudice, Francesco; Gomez Rivas, Juan; Albisinni, Simone; Soria, Francesco; Ploussard, Guillaume; Mertens, Laura S; Rajwa, Pawel; Laukhtina, Ekaterina; Pradere, Benjamin; Tully, Karl; Guerrero-Ramos, Félix; Rodríguez-Faba, Óscar; Alvarez-Maestro, Mario; Dominguez-Escrig, Jose Luis; Szydelko, Tomasz; Gomez Dos Santos, Victoria; Jiménez Cidre, Miguel Ángel; Burgos Revilla, Francisco Javier.
Afiliación
  • Subiela JD; Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain. Electronic address: jdsubiela@gmail.com.
  • Krajewski W; Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland.
  • González-Padilla DA; Department of Urology, Clínica Universidad de Navarra, Madrid, Spain.
  • Laszkiewicz J; Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland.
  • Taborda J; Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
  • Aumatell J; Servicio de Urología, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos Móstoles, Madrid, Spain.
  • Sanchez Encinas M; Servicio de Urología, Hospital Universitario Rey Juan Carlos, Universidad Rey Juan Carlos Móstoles, Madrid, Spain.
  • Basile G; Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Moschini M; Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Caño-Velasco J; Department of Urology, Hospital Universitario Gregorio Marañon, Madrid, Spain.
  • Lopez Perez E; Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
  • Del Olmo Durán P; Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
  • Gallioli A; Department of Urology, Fundaciò Puigvert, Autonomous University of Barcelona, Barcelona, Spain.
  • Tukiendorf A; Institute of Health Sciences, Opole University, Opole, Poland; University Clinical Hospital in Opole, Opole, Poland.
  • D'Andrea D; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Yuen-Chun Teoh J; S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region.
  • Serna Céspedes A; Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
  • Pichler R; Medical University of Innsbruck, Department of Urology, Comprehensive Cancer Center Innsbruck (CCCI), Innsbruck, Austria.
  • Afferi L; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
  • Del Giudice F; Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy.
  • Gomez Rivas J; Department of Urology, Hospital Clínico San Carlos, Madrid, Spain.
  • Albisinni S; Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy.
  • Soria F; Division of Urology, Department of Surgical Sciences Molinette Hospital University of Torino School of Medicine, Torino, Italy.
  • Ploussard G; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
  • Mertens LS; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Rajwa P; Department of Urology, Medical University of Silesia, Zabrze, Poland.
  • Laukhtina E; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
  • Pradere B; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
  • Tully K; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
  • Guerrero-Ramos F; Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain; ROC Clinic, Madrid, Spain; Department of Urology, Hospital Universitario HM Sanchinarro, Madrid, Spain.
  • Rodríguez-Faba Ó; Department of Urology, Fundaciò Puigvert, Autonomous University of Barcelona, Barcelona, Spain.
  • Alvarez-Maestro M; Department of Urology, Hospital Universitario La Paz, Madrid, Spain.
  • Dominguez-Escrig JL; Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
  • Szydelko T; Department of Minimally Invasive Robotic Urology, Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland.
  • Gomez Dos Santos V; Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
  • Jiménez Cidre MÁ; Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
  • Burgos Revilla FJ; Department of Urology, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcala, Madrid, Spain.
Eur Urol Oncol ; 2024 02 13.
Article en En | MEDLINE | ID: mdl-38355375
ABSTRACT

BACKGROUND:

The European Association of Urology (EAU) recommends discussing upfront radical cystectomy for all patients with very high risk (VHR) non-muscle-invasive bladder carcinoma (NMIBC), but the role of bacillus Calmette-Guérin (BCG) treatment remains controversial.

OBJECTIVE:

To analyze oncological outcomes in VHR NMIBC patients (EAU risk groups) treated with adequate BCG. DESIGN, SETTING, AND

PARTICIPANTS:

A multi-institutional retrospective study involving patients with VHR NMIBC who received adequate BCG therapy from 2007 to 2020 was conducted. OUTCOME MEASUREMENTS AND STATISTICAL

ANALYSIS:

A survival analysis estimated recurrence-free survival (RFS), progression-free survival (PFS), and the cumulative incidence of cancer-specific mortality (CSM) after accounting for other causes of mortality as competing risk events and of the overall mortality (OM). Conditional survival probabilities for 0-4 yr without events were computed. Cox regression assessed the predictors of oncological outcomes. RESULTS AND

LIMITATION:

A total of 640 patients, with a median 47 (32-67) mo follow-up for event-free individuals, were analyzed. High-grade RFS and PFS at 5 yr were 53% (49-57%) and 78% (74-82%), respectively. The cumulative incidence of CSM and OM at 5 yr was 13% (10-16%) and 16% (13-19%), respectively. Conditional RFS, PFS, overall survival, and cancer-specific survival at 4 yr were 91%, 96%, 87%, and 94%, respectively. Cox regression identified tumor grade (hazard ratio [HR] 1.54; 1.1-2) and size (HR 1.3; 1.1-1.7) as RFS predictors. Tumor multiplicity predicted RFS (HR 1.6; 1.3-2), PFS (HR 2; 1.2-3.3), and CSM (HR 2; 1.2-3.2), while age predicted OM (HR 1.48; 1.1-2).

CONCLUSIONS:

Patients with VHR NMIBC who receive adequate BCG therapy have a more favorable prognosis than predicted by EAU risk groups, especially among those with a sustained response, in whom continuing maintenance therapy emerges as a viable alternative to radical cystectomy. PATIENT

SUMMARY:

Our research shows that a sustained response to bacillus Calmette-Guérin in patients can lead to favorable outcomes, serving as a viable alternative to cystectomy for select cases.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur Urol Oncol Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Eur Urol Oncol Año: 2024 Tipo del documento: Article